6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
another O
section O
of O
the O
label O
: O
* O
New B-OSE_Labeled_AE
Primary I-OSE_Labeled_AE
Malignancies I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Venous B-OSE_Labeled_AE
Thromboembolism I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Cardiomyopathy B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Ocular B-OSE_Labeled_AE
Toxicities I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Interstitial B-OSE_Labeled_AE
Lung I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Serious O
Febrile B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Serious O
Skin B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Hyperglycemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Most O
common O
adverse O
reactions O
( O
> O
=20 O
% O
) O
for O
MEKINIST O
as O
a O
single O
agent O
include O
rash O
, O
diarrhea O
, O
and O
lymphedema O
. O

( O
6.1 O
) O
* O
Most O
common O
adverse O
reactions O
( O
> O
=20 O
% O
) O
for O
MEKINIST O
in O
combination O
with O
dabrafenib O
include O
pyrexia O
, O
chills O
, O
fatigue O
, O
rash O
, O
nausea O
, O
vomiting O
, O
diarrhea O
, O
abdominal O
pain O
, O
peripheral O
edema O
, O
cough O
, O
headache O
, O
arthralgia O
, O
night O
sweats O
, O
decreased O
appetite O
, O
constipation O
, O
and O
myalgia O
. O

( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
GlaxoSmithKline O
at O
1-888-825-5249 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
in O
the O
Warnings O
and O
Precautions O
section O
and O
below O
reflect O
exposure O
to O
MEKINIST O
as O
a O
single O
agent O
and O
in O
combination O
with O
dabrafenib O
. O

MEKINIST O
as O
a O
single O
agent O
was O
evaluated O
in O
329 O
patients O
including O
107 O
( O
33 O
% O
) O
exposed O
for O
greater O
than O
or O
equal O
to O
6 O
months O
and O
30 O
( O
9 O
% O
) O
exposed O
for O
greater O
than O
or O
equal O
to O
one O
year O
. O

MEKINIST O
as O
a O
single O
agent O
was O
studied O
in O
open-label O
, O
single-arm O
trials O
( O
N O
= O
118 O
) O
or O
in O
an O
open-label O
, O
randomized O
, O
active-controlled O
trial O
( O
N O
= O
211 O
) O
. O

The O
median O
age O
was O
54 O
years O
, O
60 O
% O
were O
male O
, O
> O
99 O
% O
were O
white O
, O
and O
all O
patients O
had O
metastatic B-Not_AE_Candidate
melanoma I-Not_AE_Candidate
. O

All O
patients O
received O
2 O
mg O
once-daily O
doses O
of O
MEKINIST O
. O

The O
incidence O
of O
RPED O
and O
RVO O
are O
obtained O
from O
the O
1,749 O
patients O
from O
all O
clinical O
trials O
with O
MEKINIST O
. O

The O
safety O
of O
MEKINIST O
in O
combination O
with O
dabrafenib O
was O
evaluated O
in O
Trial O
2 O
and O
other O
trials O
consisting O
of O
202 O
patients O
with O
BRAF O
V600 O
mutation-positive O
unresectable O
or O
metastatic B-Not_AE_Candidate
melanoma I-Not_AE_Candidate
who O
received O
MEKINIST O
2 O
mg O
orally O
once O
daily O
in O
combination O
with O
dabrafenib O
150 O
mg O
orally O
twice O
daily O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

Among O
these O
202 O
patients O
, O
68 O
( O
34 O
% O
) O
were O
exposed O
to O
MEKINIST O
and O
66 O
( O
33 O
% O
) O
were O
exposed O
to O
dabrafenib O
for O
greater O
than O
6 O
to O
12 O
months O
while O
36 O
( O
18 O
% O
) O
were O
exposed O
to O
MEKINIST O
and O
40 O
( O
20 O
% O
) O
were O
exposed O
to O
dabrafenib O
for O
greater O
than O
one O
year O
. O

The O
median O
age O
was O
54 O
years O
, O
57 O
% O
were O
male O
and O
> O
99 O
% O
were O
white O
. O

Table O
3 O
presents O
adverse O
reactions O
identified O
from O
analyses O
of O
Trial O
1 O
, O
a O
randomized O
, O
open-label O
trial O
of O
patients O
with O
BRAF O
V600E O
or O
V600K O
mutation-positive O
melanoma B-Not_AE_Candidate
receiving O
MEKINIST O
( O
N O
= O
211 O
) O
2 O
mg O
orally O
once O
daily O
or O
chemotherapy O
( O
N O
= O
99 O
) O
( O
either O
dacarbazine O
1,000 O
mg/m O
2 O
every O
3 O
weeks O
or O
paclitaxel O
175 O
mg/m O
2 O
every O
3 O
weeks O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Patients O
with O
abnormal B-Not_AE_Candidate
LVEF I-Not_AE_Candidate
, O
history O
of O
acute B-Not_AE_Candidate
coronary I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
within O
6 O
months O
, O
or O
current O
evidence O
of O
Class O
II O
or O
greater O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
( O
New O
York O
Heart O
Association O
) O
were O
excluded O
from O
Trial O
1 O
. O

The O
median O
duration O
of O
treatment O
with O
MEKINIST O
was O
4.3 O
months O
. O

In O
Trial O
1 O
, O
9 O
% O
of O
patients O
receiving O
MEKINIST O
experienced O
adverse O
reactions O
resulting O
in O
permanent O
discontinuation O
of O
trial O
medication O
. O

The O
most O
common O
adverse O
reactions O
resulting O
in O
permanent O
discontinuation O
of O
MEKINIST O
were O
decreased B-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
( I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
) O
, O
pneumonitis B-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
. O

Adverse O
reactions O
led O
to O
dose O
reductions O
in O
27 O
% O
of O
patients O
treated O
with O
MEKINIST O
. O

Rash B-OSE_Labeled_AE
and O
decreased B-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
were O
the O
most O
common O
reasons O
cited O
for O
dose O
reductions O
of O
MEKINIST O
. O

Table O
3 O
. O

Selected O
Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
Receiving O
MEKINIST O
and O
at O
a O
Higher O
Incidence O
( O
> O
=5 O
% O
) O
Than O
in O
the O
Chemotherapy O
Arm O
or O
> O
=2 O
% O
( O
Grades O
3 O
or O
4 O
) O
Adverse O
Reactions O
Adverse O
Reactions O
MEKINIST O
Chemotherapy O
N O
= O
211 O
N O
= O
99 O
All O
Gradesa O
Grades O
3 O
and O
4b O
All O
Gradesa O
Grades O
3 O
and O
4b O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
57 O
8 O
10 O
0 O
Dermatitis B-OSE_Labeled_AE
acneiform I-OSE_Labeled_AE
19 O
< O
1 O
1 O
0 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
11 O
0 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
10 O
2 O
1 O
0 O
Paronychia B-OSE_Labeled_AE
10 O
0 O
1 O
0 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
43 O
0 O
16 O
2 O
Stomatitis B-OSE_Labeled_AE
c O
15 O
2 O
2 O
0 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
d O
13 O
1 O
5 O
1 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Lymphedema B-OSE_Labeled_AE
e O
32 O
1 O
4 O
0 O
Hypertension B-OSE_Labeled_AE
15 O
12 O
7 O
3 O
Hemorrhage B-OSE_Labeled_AE
f O
13 O
< O
1 O
0 O
0 O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
4.0 O
. O
b O
Grade O
4 O
adverse O
reactions O
limited O
to O
rash B-OSE_Labeled_AE
( O
n O
= O
1 O
) O
in O
trametinib O
arm O
and O
diarrhea B-NonOSE_AE
( O
n O
= O
1 O
) O
in O
chemotherapy O
arm O
. O

c O
Includes O
the O
following O
terms O
: O
stomatitis B-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
and O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

d O
Includes O
the O
following O
terms O
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
and O
abdominal B-OSE_Labeled_AE
tenderness I-OSE_Labeled_AE
. O

e O
Includes O
the O
following O
terms O
: O
lymphedema B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
. O

f O
Includes O
the O
following O
terms O
: O
epistaxis B-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
hematochezia B-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
melena B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hemorrhoidal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
and O
conjunctival B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
. O

Other O
clinically O
important O
adverse O
reactions O
observed O
in O
< O
=10 O
% O
of O
patients O
( O
N O
= O
329 O
) O
treated O
with O
MEKINIST O
were O
: O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Bradycardia B-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Xerostomia B-OSE_Labeled_AE
. O

Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
: O
Folliculitis B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
pustular I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Rhabdomyolysis B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Dizziness B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
. O

Ocular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
. O

Table O
4 O
. O

Percent-Patient O
Incidence O
of O
Laboratory O
Abnormalities O
Occurring O
at O
a O
Higher O
Incidence O
in O
Patients O
Treated O
With O
MEKINIST O
in O
Trial O
1 O
( O
Between-Arm O
Difference O
of O
> O
=5 O
% O
[ O
All O
Grades O
] O
or O
> O
=2 O
% O
[ O
Grades O
3 O
or O
4 O
] O
a O
) O
Test O
MEKINIST O
Chemotherapy O
N O
= O
211 O
N O
= O
99 O
All O
Grades O
Grades O
3 O
and O
4 O
All O
Grades O
Grades O
3 O
and O
4 O
Increased B-OSE_Labeled_AE
aspartate O
aminotransferase I-OSE_Labeled_AE
( O
AST O
) O
60 O
2 O
16 O
1 O
Increased B-OSE_Labeled_AE
alanine I-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
( O
ALT O
) O
39 O
3 O
20 O
3 O
Hypoalbuminemia B-OSE_Labeled_AE
42 O
2 O
23 O
1 O
Anemia B-OSE_Labeled_AE
38 O
2 O
26 O
3 O
Increased B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
24 O
2 O
18 O
3 O
* O
a O
No O
Grade O
4 O
events O
were O
reported O
in O
either O
treatment O
arm O
. O

Table O
5 O
presents O
adverse O
reactions O
from O
Trial O
2 O
, O
a O
multicenter O
, O
open-label O
, O
randomized O
trial O
of O
162 O
patients O
with O
BRAF O
V600E O
or O
V600K O
mutation-positive O
melanoma B-Not_AE_Candidate
receiving O
MEKINIST O
2 O
mg O
once O
daily O
in O
combination O
with O
dabrafenib O
150 O
mg O
twice O
daily O
( O
N O
= O
55 O
) O
, O
MEKINIST O
1 O
mg O
once O
daily O
in O
combination O
with O
dabrafenib O
150 O
mg O
twice O
daily O
( O
N O
= O
54 O
) O
, O
and O
dabrafenib O
as O
a O
single O
agent O
150 O
mg O
twice O
daily O
( O
N O
= O
53 O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Patients O
with O
abnormal B-Not_AE_Candidate
LVEF I-Not_AE_Candidate
, O
history O
of O
acute B-Not_AE_Candidate
coronary I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
within O
6 O
months O
, O
current O
evidence O
of O
Class O
II O
or O
greater O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
( O
New O
York O
Heart O
Association O
) O
, O
history O
of O
RVO B-Not_AE_Candidate
, O
or O
RPED B-Not_AE_Candidate
, O
QTc B-Not_AE_Candidate
interval I-Not_AE_Candidate
> I-Not_AE_Candidate
= I-Not_AE_Candidate
4 I-Not_AE_Candidate
8 I-Not_AE_Candidate
0 I-Not_AE_Candidate
msec I-Not_AE_Candidate
, O
treatment O
refractory B-Not_AE_Candidate
hypertension I-Not_AE_Candidate
, O
uncontrolled O
arrhythmias B-Not_AE_Candidate
, O
history O
of O
pneumonitis B-Not_AE_Candidate
or O
interstitial B-Not_AE_Candidate
lung I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
or O
a O
known O
history O
of O
G B-Not_AE_Candidate
6 I-Not_AE_Candidate
PD I-Not_AE_Candidate
deficiency I-Not_AE_Candidate
were O
excluded O
. O

The O
median O
duration O
of O
treatment O
was O
10.9 O
months O
for O
both O
MEKINIST O
( O
2-mg O
once-daily O
treatment O
group O
) O
and O
dabrafenib O
when O
used O
in O
combination O
, O
10.6 O
months O
for O
both O
MEKINIST O
( O
1-mg O
once-daily O
treatment O
group O
) O
and O
dabrafenib O
when O
used O
in O
combination O
, O
and O
6.1 O
months O
for O
dabrafenib O
as O
a O
single O
agent O
. O

In O
Trial O
2 O
, O
13 O
% O
of O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
at O
the O
recommended O
dose O
experienced O
adverse O
reactions O
resulting O
in O
permanent O
discontinuation O
of O
trial O
medication O
( O
s O
) O
. O

The O
most O
common O
adverse O
reaction O
resulting O
in O
permanent O
discontinuation O
was O
pyrexia B-OSE_Labeled_AE
( O
4 O
% O
) O
. O

Adverse O
reactions O
led O
to O
dose O
reductions O
in O
49 O
% O
and O
dose O
interruptions O
in O
67 O
% O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

Pyrexia B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
and O
nausea B-OSE_Labeled_AE
were O
the O
most O
common O
reasons O
cited O
for O
dose O
reductions O
, O
and O
pyrexia B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
and O
decreased B-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
were O
the O
most O
common O
reasons O
cited O
for O
dose O
interruptions O
of O
MEKINIST O
and O
dabrafenib O
when O
used O
in O
combination O
. O

Table O
5 O
. O

Common O
Adverse O
Drug O
Reactions O
Occurring O
in O
> O
10 O
% O
( O
All O
Grades O
) O
or O
> O
=5 O
% O
( O
Grades O
3 O
or O
4 O
) O
of O
Patients O
Treated O
With O
MEKINIST O
in O
Combination O
With O
Dabrafenib O
in O
Trial O
2 O
Adverse O
Reactions O
MEKINIST O
2 O
mg O
plus O
Dabrafenib O
N O
= O
55 O
MEKINIST O
1 O
mg O
plus O
Dabrafenib O
N O
= O
54 O
Dabrafenib O
N O
= O
53 O
All O
Grades O
a O
Grades O
3 O
and O
4 O
All O
Grades O
a O
Grades O
3 O
and O
4 O
All O
Grades O
a O
Grades O
3 O
and O
4 O
General O
disorders O
and O
administrative O
site O
conditions O
Pyrexia B-OSE_Labeled_AE
71 O
5 O
69 O
9 O
26 O
0 O
Chills B-OSE_Labeled_AE
58 O
2 O
50 O
2 O
17 O
0 O
Fatigue B-OSE_Labeled_AE
53 O
4 O
57 O
2 O
40 O
6 O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
b O
31 O
0 O
28 O
0 O
17 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
c O
45 O
0 O
43 O
2 O
53 O
0 O
Night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
24 O
0 O
15 O
0 O
6 O
0 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
18 O
0 O
9 O
0 O
6 O
0 O
Dermatitis B-OSE_Labeled_AE
acneiform I-OSE_Labeled_AE
16 O
0 O
11 O
0 O
4 O
0 O
Actinic B-OSE_Labeled_AE
keratosis I-OSE_Labeled_AE
15 O
0 O
7 O
0 O
9 O
0 O
Erythema B-OSE_Labeled_AE
15 O
0 O
6 O
0 O
2 O
0 O
Pruritus B-OSE_Labeled_AE
11 O
0 O
11 O
0 O
13 O
0 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
44 O
2 O
46 O
6 O
21 O
0 O
Vomiting B-OSE_Labeled_AE
40 O
2 O
43 O
4 O
15 O
0 O
Diarrhea B-OSE_Labeled_AE
36 O
2 O
26 O
0 O
28 O
0 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
d O
33 O
2 O
24 O
2 O
21 O
2 O
Constipation B-OSE_Labeled_AE
22 O
0 O
17 O
2 O
11 O
0 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
11 O
0 O
11 O
0 O
6 O
0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
29 O
0 O
37 O
2 O
28 O
0 O
Dizziness B-OSE_Labeled_AE
16 O
0 O
13 O
0 O
9 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
29 O
0 O
11 O
0 O
21 O
0 O
Oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
13 O
0 O
7 O
0 O
0 O
0 O
Musculoskeletal B-NonOSE_AE
, I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
bone I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
27 O
0 O
44 O
0 O
34 O
0 O
Myalgia B-OSE_Labeled_AE
22 O
2 O
24 O
0 O
23 O
2 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
18 O
5 O
11 O
0 O
11 O
2 O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
16 O
0 O
2 O
0 O
4 O
0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
16 O
0 O
11 O
2 O
19 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutritional I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
22 O
0 O
30 O
0 O
19 O
0 O
Dehydration B-OSE_Labeled_AE
11 O
0 O
6 O
2 O
2 O
0 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
18 O
0 O
11 O
0 O
8 O
2 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hemorrhage B-OSE_Labeled_AE
e O
16 O
5 O
11 O
0 O
2 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
13 O
2 O
6 O
0 O
9 O
2 O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
f O
7 O
7 O
2 O
0 O
0 O
0 O
* O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
4 O
. O

* O
b O
Includes O
the O
following O
terms O
: O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
and O
lymphedema B-OSE_Labeled_AE
. O

* O
c O
Includes O
the O
following O
terms O
: O
rash B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
pruritic I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
vesicular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
maculo I-OSE_Labeled_AE
- I-OSE_Labeled_AE
papular I-OSE_Labeled_AE
. O

* O
d O
Includes O
the O
following O
terms O
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
, O
and O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
. O

* O
e O
Includes O
the O
following O
terms O
: O
brain B-OSE_Labeled_AE
stem I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
gastric B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
intracranial I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
and O
vitreous B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
. O

* O
f O
Includes O
the O
following O
terms O
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
. O

Other O
clinically O
important O
adverse O
reactions O
( O
N O
= O
202 O
) O
observed O
in O
< O
10 O
% O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
were O
: O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
transient B-OSE_Labeled_AE
blindness I-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Stomatitis B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
. O

General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
Asthenia B-OSE_Labeled_AE
. O

Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
: O
Cellulitis B-OSE_Labeled_AE
, O
folliculitis B-OSE_Labeled_AE
, O
paronychia B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
pustular I-OSE_Labeled_AE
. O

Neoplasms B-NonOSE_AE
Benign O
, O
Malignant I-NonOSE_AE
, O
and O
Unspecified O
( O
including O
cysts O
and O
polyps O
) O
: O
Skin B-OSE_Labeled_AE
papilloma I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
hyperkeratosis B-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
. O

Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Hypertension B-OSE_Labeled_AE
. O

Table O
6 O
. O

Treatment-Emergent O
Laboratory O
Abnormalities O
Occurring O
at O
> O
=10 O
% O
( O
All O
Grades O
) O
or O
> O
=2 O
% O
( O
Grades O
3 O
or O
4 O
) O
of O
Patients O
Treated O
With O
MEKINIST O
in O
Combination O
With O
Dabrafenib O
in O
Trial O
2 O
Test O
MEKINIST O
2 O
mg O
plus O
Dabrafenib O
N O
= O
55 O
MEKINIST O
1 O
mg O
plus O
Dabrafenib O
N O
= O
54 O
Dabrafenib O
N O
= O
53 O
All O
Grades O
Grades O
3 O
and O
4 O
All O
Grades O
Grades O
3 O
and O
4 O
All O
Grades O
Grades O
3 O
and O
4a O
Hematology B-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
62 O
5 O
46 O
4 O
21 O
0 O
Lymphopenia B-OSE_Labeled_AE
55 O
22 O
59 O
19 O
40 O
6 O
Neutropenia B-OSE_Labeled_AE
55 O
13 O
37 O
2 O
9 O
2 O
Anemia B-OSE_Labeled_AE
55 O
4 O
46 O
7 O
28 O
0 O
Thrombocytopenia B-OSE_Labeled_AE
31 O
4 O
31 O
2 O
8 O
0 O
Liver B-NonOSE_AE
Function I-NonOSE_AE
Tests I-NonOSE_AE
Increased B-OSE_Labeled_AE
AST I-OSE_Labeled_AE
60 O
5 O
54 O
0 O
15 O
0 O
Increased B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
60 O
2 O
67 O
6 O
26 O
2 O
Increased B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
42 O
4 O
35 O
4 O
11 O
0 O
Hyperbilirubinemia B-OSE_Labeled_AE
15 O
0 O
7 O
4 O
0 O
0 O
Chemistry B-NonOSE_AE
Hyperglycemia B-OSE_Labeled_AE
58 O
5 O
67 O
6 O
49 O
2 O
Increased B-OSE_Labeled_AE
GGT I-OSE_Labeled_AE
56 O
11 O
54 O
17 O
38 O
2 O
Hyponatremia B-OSE_Labeled_AE
55 O
11 O
48 O
15 O
36 O
2 O
Hypoalbuminemia B-OSE_Labeled_AE
53 O
0 O
43 O
2 O
23 O
0 O
Hypophosphatemia B-OSE_Labeled_AE
47 O
5 O
41 O
11 O
40 O
0 O
Hypokalemia B-OSE_Labeled_AE
29 O
2 O
15 O
2 O
23 O
6 O
Increased B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
24 O
5 O
20 O
2 O
9 O
0 O
Hypomagnesemia B-OSE_Labeled_AE
18 O
2 O
2 O
0 O
6 O
0 O
Hyperkalemia B-OSE_Labeled_AE
18 O
0 O
22 O
0 O
15 O
4 O
Hypercalcemia B-OSE_Labeled_AE
15 O
0 O
19 O
2 O
4 O
0 O
Hypocalcemia B-OSE_Labeled_AE
13 O
0 O
20 O
0 O
9 O
0 O
* O
a O
No O
Grade O
4 O
events O
were O
reported O
in O
dabrafenib O
arm O
. O

* O
ALT O
= O
Alanine O
aminotransferase O
; O
AST O
= O
Aspartate O
aminotransferase O
; O
GGT O
= O
Gamma O
glutamyltransferase O
. O

QT B-OSE_Labeled_AE
Prolongation I-OSE_Labeled_AE
: O
In O
Trial O
2 O
, O
QTcF B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
to O
> O
500 O
msec O
occurred O
in O
4 O
% O
( O
2/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
in O
2 O
% O
( O
1/53 O
) O
of O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

The O
QTcF B-OSE_Labeled_AE
was O
increased I-OSE_Labeled_AE
more O
than O
60 O
msec O
from O
baseline O
in O
13 O
% O
( O
7/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
2 O
% O
( O
1/53 O
) O
of O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

